CYSTARAN (cysteamine HCl)
OPHTHALMIC - CYSTINE DEPLETING AGENTS · BENIGN CYSTINOSIS WITH CORNEAL CYSTINE CRYSTAL ACCUMULATION
LEADIANT BIOSCI
Drug class
Ophthalmic - Cystine Depleting Agents
Ophthalmic cystine-depleting agents are topical ocular therapeutics formulated to reduce the pathological accumulation of cystine within ocular tissues. Read more about Ophthalmic - Cystine Depleting Agents
2 drugs in this class 2 manufacturers
Drugs in Ophthalmic - Cystine Depleting Agents
CYSTADROPS (cysteamine HCl)
OPHTHALMIC - CYSTINE DEPLETING AGENTS · BENIGN CYSTINOSIS WITH CORNEAL CYSTINE CRYSTAL ACCUMULATION
RECORDATI RARE
Filter & compare in the drug finder →
Opens the drug finder with Ophthalmic - Cystine Depleting Agents preselected. Add indication or manufacturer filters there.
Ophthalmic cystine-depleting agents are topical ocular therapeutics formulated to reduce the pathological accumulation of cystine within ocular tissues.
Agents in this class, notably topical cysteamine formulations, function via a thiol-disulfide interchange reaction that converts accumulated cystine into cysteine and a cysteine-cysteamine mixed disulfide, enabling these smaller molecules to exit cellular lysosomes.
This therapeutic class is primarily indicated for the management of corneal cystine crystal accumulation in pediatric and adult patients with cystinosis, a rare autosomal recessive metabolic disorder.
Because systemic cystine-depleting therapies fail to adequately penetrate the avascular cornea, topical ophthalmic delivery provides targeted local clearance of crystal deposits to alleviate ocular symptoms and preserve visual function.
-
fda.gov
Ophthalmic cystine-depleting agents are topical ocular therapeutics formulated to reduce the pathological accumulation of cystine within ocular tissues Because systemic cystine-depleting therapies fail to adequately penetrate the avascular cornea, topical ophthalmic delivery provides targeted local clearance of crystal deposits to alleviate ocular symptoms and preserve visual function
-
nih.gov
Ophthalmic cystine-depleting agents are topical ocular therapeutics formulated to reduce the pathological accumulation of cystine within ocular tissues Agents in this class, notably topical cysteamine formulations, function via a thiol-disulfide interchange reaction that converts accumulated cystine into cysteine and a cysteine-cysteamine mixed disulfide, enabling these smaller molecules to exit cellular lysosomes This therapeutic class is primarily indicated for the management of corneal cystin...
-
nih.gov
Agents in this class, notably topical cysteamine formulations, function via a thiol-disulfide interchange reaction that converts accumulated cystine into cysteine and a cysteine-cysteamine mixed disulfide, enabling these smaller molecules to exit cellular lysosomes
-
fda.gov
This therapeutic class is primarily indicated for the management of corneal cystine crystal accumulation in pediatric and adult patients with cystinosis, a rare autosomal recessive metabolic disorder
-
genome.gov
Because systemic cystine-depleting therapies fail to adequately penetrate the avascular cornea, topical ophthalmic delivery provides targeted local clearance of crystal deposits to alleviate ocular symptoms and preserve visual function
Sign in to follow this class
Following a drug class requires a free Physicians Office Resource account.